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Introduction: We investigated dose-dense docetaxel and cisplatin
in patients with measurable non-small cell lung cancer in a random-
ized phase II study without [A] or with [B] a putative chemopro-
tective agent, BNP7787.
Patients and Methods: Chemotherapy-naive patients with stage
IIIB (effusion) or IV, performance status 0 to 1, and adequate organ
function were eligible. Treatment with docetaxel 75 mg/m2 followed
by cisplatin 75 mg/m2 over 1 hour day 1 with darbepoetin 200 g
day 1 and pegfilgrastim 6 mg day 2 without/with BNP7787 before
cisplatin was repeated every other week for up to 6 cycles. The
primary end point was to differentiate between grade 2 neurotox-
icity rates of 30% on [A] and 10% on [B]. Feasibility was prospec-
tively defined as febrile neutropenia in 10% of patients and 1
treatment delay per cycles 1 to 3 and 4 to 6 in 20% of patients.
Results: Of 160 patients enrolled, 5 never started therapy and 4 were
ineligible. Neurotoxicity grade2 occurred in 32% on [A] and 29%
on [B]. The incidence of febrile neutropenia was 4% on [A] and 3%
on [B]. Treatment delays occurred in 13% and 20% of patients on
[A] and [B], respectively. Completion rates for 3/6 cycles were
84%/51% on [A] and 84%/53% on [B]. Objective response rates
were 55% on [A] and 51% on [B]. Median progression-free/overall
survival times were 5.5/10.7 on [A] and 6.5/14.1 month on [B].
Conclusions: This dose-dense treatment regimen is active, feasible,
and tolerable. Its further investigation in the curative setting in
non-small cell lung cancer should be considered. BNP7787 did not
result in significant protection from neurotoxicity.
Key Words: Phase II, Dose-dense, Docetaxel, Cisplatin, Non-small
cell lung cancer.
(J Thorac Oncol. 2008;3: 1159–1165)
Lung cancer remains the leading cause of cancer deaths inboth males and females in the United States.1 Many
patients present with advanced non-small cell lung cancer
(NSCLC) because of malignant effusions (stage IIIB) or
distant metastatic disease (stage IV). The International Asso-
ciation for the Study of Lung Cancer recently suggested
reclassifying malignant pleural or pericardial effusions from
T4 to M1, effectively making this extent of disease stage IV.2
Front-line chemotherapy with two-drug combinations given
every 3 weeks for a finite number of cycles is the standard of
care, but no individual two-drug combination warrants des-
ignation as the clear, evidence-based standard regimen.3 In-
dividual randomized trials and a recent meta-analysis suggest
that cisplatin-based chemotherapy is modestly but signifi-
cantly superior to carboplatin-based chemotherapy as first-
line therapy for patients with advanced NSCLC.4 Docetaxel
is approved by the Food and Drug Administration for first-
and second-line treatment of NSCLC. In the first line setting,
docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks
resulted in an objective response rate of 32% and a median
survival of 11.3 months in a multinational phase III study.5
Dose-dense chemotherapy is considered a validated
treatment concept in adjuvant breast cancer management.6
Phase I and II studies of docetaxel plus another drug (carbo-
platin, vinorelbine, or gemcitabine) every 2 weeks have
resulted in high objective response rates but dose-limiting
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neutropenia and neurosensory toxicity.7–9 Although the use of
filgrastim reduces the limitation of neutropenia, neurotoxicity
remains a concern. BNP7787 (disodium 2, 2-dithio-bis-
ethane sulfonate) was developed as a novel putative chemo-
protective agent.10–13 Prior clinical experience with BNP7787
in patients receiving cisplatin 75 mg/m2 and paclitaxel 175
mg/m2 suggested that it protects against neurotoxicity and
nephrotoxicity without abrogating tumor response.14 In phase
I, the doses of BNP7787 ranged from 4.1 to 41 g/m2 without
a maximum tolerated dose being reached. Schilsky et al. used
18.4 g/m2.14 On the basis of pharmacologic data, there was no
scientific rationale to continue dosing BNP7787 based on
body surface area. This study explored the utility of a fixed
dose of 40 g for BNP7787 based on the mean body surface
area from prior studies plus one standard deviation: (1.87 
0.22 m2)  18.4 g/m2, rounded up.
The rationale for this phase II study was to develop a
dose-dense regimen in advanced NSCLC that could ulti-
mately also be used for earlier stage disease. Patients were
randomized to receive docetaxel and cisplatin without [A] or
with [B] BNP7787. We anticipated an incidence of grade 2
neurotoxicity of 30% in [A] and designed the study to detect
a decrease to 10% in [B]. Other primary objectives were to
assess the feasibility (defined by febrile neutropenia and
treatment delays) and the objective response rate of dose-
dense docetaxel and cisplatin without and with BNP7787 in
patients with advanced NSCLC. Secondary objectives were
to determine survival and progression-free survival as well as
the toxicity profile of this treatment regimen.
PATIENTS AND METHODS
Patient Eligibility
All patients had measurable disease and pathologically
documented NSCLC stage IIIB because of malignant effu-
sions or stage IV disease. Prior chemotherapy was not al-
lowed. Prior radiation therapy was only acceptable for brain
metastasis, but the brain metastasis had to be under control
(patient neurologically stable and off steroids). Female pa-
tients who were pregnant or nursing were excluded. Other
eligibility criteria included: age 18 years; Eastern Cooper-
ative Oncology Group (ECOG) performance status 0 to 1; no
neuropathy grade 2; and no concurrent other malignancy.
The required laboratory values at entry were: absolute neu-
trophil count (ANC) 1500/L; platelet count 100,000/
L; serum creatinine  upper limit of normal (ULN); total
bilirubin 1.5 mg/dl; serum glutamic-oxaloacetic transami-
nase (SGOT) [aspartate transaminase {AST}] 1.5 ULN;
and alkaline phosphatase 2.5ULN. Each patient had to
give written informed consent. The study had to be approved
by the Institutional Review Board of each participating insti-
tution.
Treatment Plan
This was a randomized phase II study with 2 treatment
arms: [A] docetaxel 75 mg/m2 intravenously (IV) over 1 hour
on day 1 immediately followed by cisplatin 75 mg/m2 IV
over 1 hour on day 1 with adequate hydration, darbepoetin
alfa 200 g subcutaneously (SC) on day 1 if hemoglobin11
g/dl, and pegfilgrastim 6 mg SC on day 2, every 2 weeks for
6 cycles; and [B] docetaxel 75 mg/m2 IV over 1 hour on day
1 immediately followed by BNP7787 at 40 g IV over 30
minutes on day 1 immediately followed by cisplatin 75
mg/m2 IV over 1 hour on day 1 with adequate hydration,
darbepoetin alfa 200 g SC on day 1 if hemoglobin11 g/dl,
and pegfilgrastim 6 mg SC on day 2, every 2 weeks for 6
cycles. Adequate hydration was defined as at least 1 liter of
normal saline IV before and after cisplatin. Darbepoetin at
200 g was started for hemoglobin11 g/dl and was held for
hemoglobin 13 g/dl during treatment; subsequently darbe-
poetin was restarted at 150 g for hemoglobin 12 g/dl. If
the hemoglobin increased by more than 1.0 g/dl in a 2-week
period, the darbepoetin dose was decreased by 25%. Treat-
ment was repeated every 2 weeks (1 cycle  2 weeks) for 6
cycles unless there was intolerable toxicity or disease pro-
gression. BNP7787 was provided by BioNumerik Pharma-
ceuticals (San Antonio, Texas). Darbepoetin and pegfilgras-
tim were provided by Amgen (Thousand Oaks, California).
All other drugs were obtained from commercial sources.
Ancillary medications included dexamethasone, serotonin
subtype 3 (5-HT3) receptor antagonists, aprepitant, and
bisphosphonates for bone metastases. Patients requiring radi-
ation therapy during protocol treatment were considered to
have progressed and were removed from protocol treatment.
On day 1 of subsequent cycles, treatment was held for
ANC 1000/L or platelets 100,000/L and counts were
repeated twice weekly until these minimal values were
achieved. If treatment was held for more than 1 week due to
hematologic toxicity or the patient developed neutropenic
fever [defined as ANC 1000/L at the time of documented
temperature 38.5°C (100.8°F)], the subsequent doses were
docetaxel 60 mg/m2, and cisplatin 60 mg/m2. The docetaxel
dose remained at 75 mg/m2 for the following liver function
tests: bilirubin 1.5 mg/dl and alkaline phosphatase 5
ULN and SGOT (AST) 1.5 ULN. The docetaxel dose
was reduced by 25% for the following values: bilirubin 1.5
mg/dl and alkaline phosphatase5 ULN and SGOT (AST)
1.6 to 5 ULN. When these margins were exceeded (biliru-
bin 1.5 mg/dl or alkaline phosphatase 5 ULN or SGOT
(AST) 5 ULN), docetaxel was held until values returned
to bilirubin 1.5 mg/dl and alkaline phosphatase 5 ULN
and SGOT (AST) 5 ULN and then dose reduced by 25%.
Cisplatin was dosed according to serum creatinine: 100% for
creatinine 1.5 mg/dl, 50% for creatinine 1.6 to 1.9 mg/dl,
and 0% for creatinine 2.0 mg/dl. Docetaxel and cisplatin
were given at full dose unless neurotoxicity exceeded grade 1.
For grade 2 neurotoxicity, both drugs were held and only
continued at 75% of the dose in the prior cycle when neuro-
toxicity returned to grade 1. Protocol therapy was discon-
tinued for grade 3 or 4 neurotoxicity, including ototoxicity,
and for allergic reactions grade 3. If a patient developed
other grade 3 or 4 nonhematologic toxicity, chemotherapy was
held until the toxicity resolved to grade1 and then resumed at
75% of the previous doses of docetaxel and cisplatin.
Clinical Evaluation
Before enrollment on study and before each treatment
cycle, a comprehensive history and physical examination
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were performed, and complete blood counts with differential
and serum chemistries were obtained. A neurologic exami-
nation by a physician, physician assistant or nurse practitio-
ner and a patient neurologic questionnaire15 were docu-
mented on day 1 of each treatment cycle. On the
questionnaire, the patients checked boxes according to their
perceived severity of neurologic dysfunction for hands and
feet and for arms and legs. Audiograms were obtained before
registration and before cycle 3. Blood counts were obtained
weekly while on treatment. Staging studies were performed
before enrollment and after 3 and 6 cycles of therapy. The
Response Evaluation Criteria in Solid Tumors by the Na-
tional Cancer Institute were applied.16 The Common Termi-
nology Criteria for Adverse Events (CTCAE; Version 3.0)
from the National Cancer Institute (http://ctep.cancer.gov)
were used. After the protocol therapy was completed, patients
were followed at least every 3 months for 1 year and then
every 6 months until progression or death for 2 years.
Statistical Analyses
To detect a decrease in the incidence rate of grade 2
neurotoxicity from 30% in [A] to 10% in [B] with 90% power
for a test conducted at the 0.10 level of significance (two-
tailed), 76 patients were needed in each treatment arm.
Feasibility was prospectively defined by the following mar-
gins in the incidence of febrile neutropenia and delays of
treatment cycles due to incomplete blood count recovery:
febrile neutropenia in 10% of patients; and no more than
one treatment delay in20% of patients during the first three
treatment cycles and no more than one treatment delay in
20% of patients during cycles 4 through 6. In addition, the
study was designed to determine whether each treatment
regimen had sufficient activity to merit further investigation:
With 76 patients per arm, the study had 90% power to
differentiate between true response rates of 20% versus
35% at a two-tailed significance level of 0.10. Thus, we
defined prospectively that if 21 patients of the 76 patients
per treatment arm responded to treatment, the treatment
regimen would be considered worthy of further investigation;
the actual Type I and II errors of this decision rule are 0.068
and 0.069, respectively. Kaplan-Meier curves were used to
describe progression-free survival and overall survival.17 Pro-
gression-free survival was the time from randomization until
disease progression, death, or last known follow-up. Survival
was the time between randomization and death of any cause.
RESULTS
Patient Characteristics
Between August 2004 and March 2006, 160 patients
were randomized to receive dose-dense docetaxel and cispla-
tin without [A] or with [B] BNP7787. Five patients never
started treatment: 3 in [A] and 2 in [B]. Four patients were
ineligible for this study: One patient in [A] had B-cell
lymphoma; one patient in [B] received previous thoracic
radiation therapy; one patient in [B] had neuropathy grade
2 when entering the study; and one patient in [B] had stage IA
disease. The demographic and baseline clinical characteristics
of the 151 eligible and treated patients are shown in Table 1.
Treatment
Thirty nine patients (51%) in [A] and 40 patients (53%)
in [B] completed 6 cycles of chemotherapy. Table 2 provides
a summary of the number of cycles administered to the
patients and the percentage of patients receiving treatment on
time (2 week interval). After cycle 3 (week 6), patients were
evaluated for tumor response, and 12 (16%) patients in [A]
and 14 (19%) patients in [B] went off protocol for progressive
disease. Grade 3 or 4 nonhematologic toxicities prompted
discontinuation of protocol therapy in 16 (21%) patients in
[A] and 9 (12%) patients in [B].
TABLE 1. Patient Demographic and Initial Clinical
Characteristics
Characteristics
Arm A
(n  76)
Arm B
(n  75)
Overall
(n  151)
Sex
Male 46 (61%) 53 (71%) 99 (66%)
Female 30 (39%) 22 (29%) 52 (34%)
Age
40 3 (4%) 2 (3%) 5 (3%)
40–49 9 (12%) 12 (16%) 21 (14%)
50–59 21 (28%) 19 (25%) 40 (26%)
60–69 33 (43%) 27 (36%) 60 (40%)
70 10 (13%) 15 (20%) 25 (17%)
Median (range) 62 (38–77) 62 (30–88) 62 (30–88)
Race
White 65 (86%) 61 (81%) 126 (83%)
Black 11 (14%) 12 (16%) 23 (15%)
Asian 0 (0%) 1 (1%) 1 (1%)
Native American 0 (0%) 1 (1%) 1 (1%)
Carcinoma type
Adeno 35 (46%) 38 (51%) 73 (48%)
Squamous 13 (17%) 21 (28%) 34 (23%)
Undifferentiated 22 (29%) 12 (16%) 34 (23%)
Bronchoalveolar 0 (0%) 1 (1%) 1 (1%)
Non-small cella 6 (8%) 3 (4%) 9 (6%)
Performance status
0 36 (47%) 33 (44%) 69 (46%)
1 40 (53%) 42 (56%) 82 (54%)
Stage
Stage IIIB 6 (8%) 7 (9%) 13 (9%)
Stage IV 70 (92%) 68 (91%) 138 (91%)
a Not otherwise specified.
TABLE 2. Number of Patients by Chemotherapy Cycle and
Percentage of Patients Receiving Cycle on Time
Cycles
Received
Arm A
(n  76)
Arm B
(n  75)
Overall
(n  151)
2 71 (90%) 67 (94%) 138 (92%)
3 64 (92%) 63 (90%) 127 (91%)
4 52 (90%) 48 (88%) 100 (89%)
5 49 (86%) 44 (66%) 93 (76%)
6 39 (87%) 40 (85%) 79 (86%)
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Neurotoxicity
The incidence rates of grade2 neuropathy (graded by
health care providers according to the CTCAE) for all cycles
by treatment arm are summarized in Table 3. The patients on
the trial reported their experience on a neurologic question-
naire, and the incidence rates of moderate to severe neurop-
athy interfering with activities of daily living are listed for all
cycles by treatment arm in Table 4. The p-values in Tables 3
and 4 are from two-tailed 2 tests on the difference of
incidence rates between treatment arms. Logistic regression
models were further fit to test the effect of treatment arms on
the incidences of neuropathy adjusting for covariates of age,
gender, race, performance status, initial diagnosis, presence
of malignant effusion, and stage. No treatment effect was
detected at a two-tailed significance level of 0.10.
Feasibility
Three (4%) patients in [A] and 2 (3%) patients in [B]
experienced treatment related febrile neutropenia; this in-
cluded the ineligible patient in [B] who had prior thoracic
radiation therapy. This incidence rate of febrile neutropenia
met the prospectively defined margin of 10% of patients.
Treatment delays in cycles 1 through 3 and cycles 4 through
6 were separately assessed because of the tumor response
evaluation between cycles 3 and 4: The experience of treat-
ment delays due to toxicity also met the prospectively set
criteria of no more than one delay in20% of patients during
cycles 1 through 3 and no more than one delay in 20% of
patients during cycles 4 through 6, except for one patient in
whom both cycles 5 and 6 were delayed.
Response
Table 5 shows the response to therapy. The complete
response rate was 3% on both arms. The partial response rates
were 52% and 48% on [A] and [B], respectively. The reasons
for inadequate assessments of response included patient re-
fusal to continue on protocol therapy (n  5), adverse event
(n 1), early deaths (n 2), and missing data (n 4). These
inadequately assessed patients were included in the denomi-
nators for the calculation of response rates.
Survival
The median follow-up time is 21.7 months. Table 6
summarizes progression-free and overall survival times as
well as 1-year survival rates. Figure 1 depicts the overall
survival by treatment arm. For the entire population of 151
patients, the overall median survival time was 11.0 months
(95% confidence interval, CI, 8.4–14.4 months), the 1-year
survival rate was 45.0% (95% CI, 37.0–52.7%), and the
2-year survival rate was 22.8% (95% CI, 15.8–30.6%).
Toxicity
The toxicity assessment included all 155 patients (151
eligible and 4 ineligible patients) who received the protocol
TABLE 3. Incidence of Neuropathy Grade 2 Assessed by
the Common Terminology Criteria for Adverse Events
Neuropathy
Arm A
(n  76)
Arm B
(n  75) pa
Motor 0.50
N 12 (16%) 15 (20%)
95% CI 8–26% 12–31%
Sensory 0.27
N 21 (28%) 15 (20%)
95% CI 18–39% 12–31%
Either motor or sensory 0.76
N 24 (32%) 22 (29%)
95% CI 21–43% 19–41%
CI, confidence interval.
a p-Values are two-sided p-values from 2 tests on the association of treatments
arms and incidence rates.
TABLE 4. Incidence of Moderate to Severe Neuropathy
Assessed by the Patient Neurological Questionnaire
Neuropathy Arm A (n  76) Arm B (n  75) Pa
Hands and feet 0.44
N 17 (22%) 13 (17%)
95% CI 14–33% 10–28%
Arms and legs 0.81
N 14 (18%) 15 (20%)
95% CI 10–29% 12–31%
Either hands and feet
or arms and legs
0.89
N 21 (28%) 20 (27%)
95% CI 18–39% 17–38%
CI, confidence interval.
a p-Values are two-sided p-values from 2 tests on the association of treatments
arms and incidence rates.
TABLE 5. Response to Therapy
Best Response
Arm A
(n  76)
Arm B
(n  75)
Complete response 2 (3%) 2 (3%)
Partial response 40 (52%) 36 (48%)
Stable disease 23 (30%) 15 (20%)
Progressive disease 9 (12%) 12 (16%)
Inadequately assessed 2 (3%) 10 (13%)
Objective response rate 55% 51%
(95% CI) (43–67%) (39–62%)
CI, confidence interval.
TABLE 6. Progression-Free Survival (PFS) and Overall
Survival (OS)
Arm
Patients
(n)
Events
(n)
Median in Months
(95% CI)
1-Year Survival Rates
(%) (95% CI)
PFS
A 76 74 5.5 (4.3–6.9) 9.2 (4.1–17.0)
B 75 70 6.5 (5.0–7.8) 18.7 (10.8–28.2)
OS
A 76 64 10.7 (8.2–12.2) 39.5 (28.5–50.2)
B 75 54 14.1 (7.1–17.0) 50.7 (38.9–61.3)
CI, confidence interval.
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treatment. Treatment-related adverse events (other than neu-
rotoxicity) of grade 3 or 4 severity were infrequent (Table 7).
Because the incidence of grade 3 and 4 nephrotoxicity was
1% in both arms, we also assessed lower grades: grade 1
toxicity occurred in 6 patients (8%) each in [A] and [B]; and
grade 2 toxicity was encountered in 14 (18%) patients in [A]
and in 7 (9%) patients in [B]. Four fatal (grade 5) events were
encountered: [A] cycle 2, cardiac arrhythmia possibly related
to treatment; [A] cycle 5, pneumonia leading to sepsis com-
plicated by hypotension and respiratory failure; [B] cycle 2,
neutropenic fever; and [B] cycle 3, neutropenia complicated
by pneumonia and adult respiratory distress syndrome in an
ineligible patient (prior thoracic radiation therapy) who re-
fused intubation for respiratory failure.
DISCUSSION
This dose-dense treatment regimen appears active, fea-
sible, tolerable, and worthy of further investigation in
NSCLC. The efficacy of this dose-dense regimen appears
promising with an objective response rate of 53%, an overall
median survival time of 11 months, and a 1-year survival rate
of 45% for the entire population of 151 patients. The response
rates observed in this study are higher than those seen in prior
Cancer and Leukemia Group B (CALGB) or other coopera-
tive group trials with similar patients, including the study by
Fossella et al. of the same doses of docetaxel and cisplatin
given every 3 weeks.3,5,18,19 In the recent meta-analysis of
cisplatin based versus carboplatin-based chemotherapy in
first-line treatment of advanced NSCLC, the median survival
times were 9.1 versus 8.4 months, respectively.4 However,
direct comparisons between this dose-dense and other studies
can not be made because this requires a phase III trial.
The majority of patients (127 or 84%) received at least
3 cycles and more than half (79 or 52%) completed 6 cycles
(Table 2). The incidence of febrile neutropenia was 5%.
However, several caveats should be considered. The median
age of the patients in this study was younger than the median
age in the entire patient population with advanced NSCLC,
and only 17% of patients were 70 of age (Table 1). The
patients in this trial had a good performance status (ECOG,
0–1), which is powerful prognostic indicator in NSCLC.
Clinicians evaluating patients for this study may have applied
a selection bias by excluding patients with comorbid condi-
tions that were not formally captured in the data collection.
However, these caveats apply to cooperative group trials in
general. For instance, patients age 70 accounted for only
15% of patients in the ECOG trial 5592 of cisplatin-based
therapy.20 It is also not unusual to limit accrual to patients
with a performance status 0 to 1 in trials with more rigorous
therapy such as paclitaxel/carboplatin with bevacizumab.18
Because we encountered 4 toxic deaths, we caution against
using this regimen in patients with a performance status 1.
The pathophysiology of peripheral neuropathy is
poorly understood, but one major contributor is thought to
consist of alteration in microtubulin function.21 BNP7787
was developed to preserve tubulin function.10 Although neu-
ropathy is a common clinical problem, effective therapies to
deal with this toxicity are limited.15 We anticipated an inci-
dence of grade 2 neurotoxicity of 30% in [A] and powered
the study to detect a decrease to 10% in [B]. The combined
sensory and motor neurotoxicity without BNP7787 in [A]
was 32% with the confidence interval as shown in Table 3.
The addition of BNP7787 in [B] did not result in a significant
protection from grade 2 neurotoxicity. As pointed out by
FIGURE 1. Overall survival.
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Wieand, randomized phase II trials are often powered to
detect a substantial benefit but may fail to identify an exper-
imental regimen with only moderate (but possibly clinically
relevant) improvement over standard therapy.22
Although patient characteristics in [A] and [B] were
balanced (Table 1), a formal statistical comparison for sec-
ondary endpoints of response rates and survival times is not
presented because of the limitations of the randomized phase
II design: The apparent difference in median survival times
between 10.7 months in [A] versus 14.1 month in [B] (Table
6 and Figure 1) will require confirmation in a phase III trial.
A review of adverse events (Table 7) reveals fewer grade 3 or
4 events in arm B for nausea, vomiting, dehydration, hypo-
kalemia, and hypomagnesemia; while this is intriguing, a
statistical comparison was not undertaken because this was
not a phase III trial. Constitutional symptoms were more
common in arm B which would have to be evaluated in
further investigations of BNP7787. The incidence of grade 3
and 4 nephrotoxicity was remarkably low in both arms, but
the incidence of grade 2 nephrotoxicity may be less with
BNP7787.
Although the hematologic toxicity was generally mild
with the use of pegfilgrastim and darbepoetin, the neuropathy
remains an obstacle to the further development of this treat-
ment regimen. The incidence of neuropathy recorded by the
CTCAE and the incidence of self-reported neuropathy were
substantial when assessed for up to 6 cycles of treatment.
Recently, an argument has been made to limit first-line
therapy for advanced NSCLC to 4 cycles.23 Treatment is also
usually limited to 4 cycles in the adjuvant setting. Therefore,
we also reviewed the incidence rates of grade 2 neuropathy
according to the CTCAE for 4 cycles of treatment: motor,
sensory, and either motor or sensory toxicity occurred in 5
(7%), 9 (12%), and 13 (17%) patients in [A] and in 10 (13%),
9 (12%), and 16 (21%) patients in [B]. Besides for the
treatment of advanced NSCLC, this dose-dense regimen may
be considered for the adjuvant, neoadjuvant or induction
settings because the higher response rates of this dose-dense
therapy may result in higher cure rates in lower stage disease.
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TABLE 7. Grade 3 and 4 Treatment Related Adverse Events
by Arm
Arm Grade 3 N (%) Grade 4 N (%)
WBC
A 0 0
B 2 (3) 0
Neutrophils
A 2 (3) 1 (1)
B 4 (5) 3 (4)
Lymphocytes
A 5 (6) 0
B 2 (3) 0
Platelets
A 4 (5) 0
B 2 (3) 1 (1)
Hemoglobin
A 9 (12) 0
B 8 (10) 1 (1)
Constitutional
A 3 (4) 0
B 13 (17) 0
Dehydration
A 12 (16) 1 (1)
B 6 (8) 1 (1)
Nausea
A 13 (17) 0
B 8 (10) 0
Vomiting
A 7 (9) 0
B 2 (3) 0
Hyperglycemia
A 7 (9) 1 (1)
B 7 (9) 1 (1)
Hypokalemia
A 8 (10) 3 (4)
B 5 (6) 1 (1)
Hypomagnesemia
A 9 (12) 0
B 0 0
Creatinine
A 0 1 (1)
B 0 0
Renal failure
A 1 (1) 0
B 0 0
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